AQST Aquestive Therapeutics Forecast, Technical & Fundamental Analysis
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs... Show more
AQST is expected to report earnings to rise 50.86% to -10 cents per share on August 04
Q2'26
Est.
$-0.11
Q1'26
Beat
by $0.06
Q4'25
Missed
by $0.13
Q3'25
Est.
$-0.14
Q2'25
Beat
by $0.03
The last earnings report on May 13 showed earnings per share of -7 cents, beating the estimate of -12 cents. With 1.22M shares outstanding, the current market capitalization sits at 523.13M.
A.I. Advisor
published General Information
General Information
a developer thin film pharmaceutical and over the counter drug products
A.I.dvisor indicates that over the last year, AQST has been loosely correlated with SXTC. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AQST jumps, then SXTC could also see price increases.
AQST sees its Stochastic Oscillator climbs out of oversold territory
On June 10, 2026, the Stochastic Oscillator for AQST moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 67 instances where the indicator left the oversold zone. In of the 67 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 11, 2026. You may want to consider a long position or call options on AQST as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AQST just turned positive on June 11, 2026. Looking at past instances where AQST's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
AQST moved above its 50-day moving average on June 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AQST advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for AQST moved out of overbought territory on May 15, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The 10-day moving average for AQST crossed bearishly below the 50-day moving average on May 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQST declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AQST broke above its upper Bollinger Band on June 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AQST entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (144.130). P/E Ratio (0.000) is within average values for comparable stocks, (97.681). AQST's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.601). AQST has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (9.434) is also within normal values, averaging (95.029).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AQST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
